2042 – SELco® TRAb human 1 step
MEDIPAN SELco® TRAb human is a competitive radio-receptor assay used for the quantitative determination of Thyrotropin (TSH) receptor autoantibodies in human serum.
Thyrotropin (TSH) receptor autoantibodies (TRAb), a hallmark of Graves’ disease, provides an effective means for the disease’ diagnosis: these autoantibodies mimic effects of TSH on the thyroid cell leading to increased blood levels of thyroid hormones thyroxine (T4) and triiodothyronine (T3). Detection and quantification of these antibodies provide a valuable means for the differential diagnosis of hyperthyroidism and control of Graves’ disease. This differential diagnosis may be applied pre- and post- treatment by anti-thyroid drugs, 131-radioiodine or surgery.
Depending on the TRAb concentration, pregnant women with Grave’s disease stand the risk of transferring their autoantibodies to the foetus via the placental; the higher the mother’s TRAb concentration, the greater the risk of transfer to the foetus and subsequent development of Grave’s diseases in the uterus, leading to congenital hyperthyroidism.
|Title||SELco® TRAb human 1 step|
|Description||Radioimmunoassay for the quantitative determination of antibodies against TSH receptor (TRAb) in human serum|
|Format||Coated tube technology|
|Total incubation time||120 min.|
|Sample volume||100 µL|
|No. of determinations||100 (93 x 1) + 5 x Calibrators + 2 x Controls|